Patents Assigned to Max-Delbruck-Centrum fur Molekulare Medizin
-
Patent number: 10975136Abstract: The present invention relates to the field of genetic engineering, in particular, to a transposon-based transfection kit suitable for transfection of primary cells, such as T cells, comprising mRNA encoding a transposase, or reagents for generating mRNA encoding said transposase, as well as minicircle DNA comprising the transposon. The invention also relates to a nucleic acid, preferably, a DNA minicircle, comprising a transposon, wherein the transposon encodes a protein and at least one miRNA, wherein the sequences encoding the miRNA are located in an intron and expression of the protein and the miRNA is regulated by the same promoter. The invention also provides a population of cells obtainable with the method of the invention. Methods of transfection are also provided, as well as medical use, e.g. in immunotherapy, in particular, in adoptive T cell therapy or T cell receptor (TCR) or chimeric antigen receptor (CAR) gene therapy.Type: GrantFiled: March 15, 2017Date of Patent: April 13, 2021Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-GemeinschaftInventors: Wolfgang Uckert, Mario Bunse, Julian Clauss, Zsuzsanna Izsvák
-
Publication number: 20210061876Abstract: The present invention pertains to antigen recognizing constructs against tumor specific proteasome splicing variants. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for tumor cells carrying antigenic epitopes generated by proteasome peptide splicing of tumor specific antigens. The TCRs of the invention, and antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of proliferative diseases, preferably for the treatment of cancer. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.Type: ApplicationFiled: January 2, 2019Publication date: March 4, 2021Applicants: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Imperial College Innovations Limited, Charité - Universitätsmedizin BerlinInventors: Thomas BLANKENSTEIN, Gerald WILLIMSKY, Juliane LIEPE, Peter Michael KLOETZEL, Michele MISHTO, Christin BEIER
-
Patent number: 10851172Abstract: A method of treating a medical disorder associated with the presence of pathogenic B cells expressing B cell maturation antigen (BCMA), the method comprising administering to a subject an isolated antibody or antibody fragment comprising specific VH and VL domain complementary determining region (CDR) sequences, wherein the antibody or fragment thereof specifically binds an epitope of the extracellular domain of CD269 (BCMA).Type: GrantFiled: October 25, 2018Date of Patent: December 1, 2020Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFTInventors: Felix Oden, Stephen Marino, Oliver Daumke
-
Patent number: 10781243Abstract: The present invention relates to the field of immunotherapy, in particular adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer. The invention provides a nucleic acid encoding at least one T cell receptor alpha chain construct and/or TCR beta chain construct of a TCR construct capable of specifically binding to an epitope from NY-ESO-1 (also designated CTAG-1) in complex with a human MHC, wherein the TCR alpha chain construct and/or the TCR beta chain construct comprises a complementarity determining region 3 (CDR3) having at least 90% sequence identity to an amino acid selected from SEQ ID NO: 1-20. The invention provides TCR constructs restricted to an epitope from NY-ESO-1 presented on MHC I, and, for the first time, TCR constructs restricted to an epitope from NY-ESO-1 presented on MHC II molecules, and thus enables a combined adoptive T cell therapy with both recombinant CD4+ and re-combinant CD8+ T cells.Type: GrantFiled: March 11, 2016Date of Patent: September 22, 2020Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFTInventors: Thomas Blankenstein, Lucia Poncette, Xiaojing Chen
-
XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME
Publication number: 20200262847Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: ApplicationFiled: May 6, 2020Publication date: August 20, 2020Applicants: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Michael BADER, Edgar SPECKER, Susann MATTHES, Anja SCHÜTZ, Keven MALLOW, Maik GROHMANN, Marc NAZARÉ -
Patent number: 10745486Abstract: The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.Type: GrantFiled: December 13, 2018Date of Patent: August 18, 2020Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZINInventors: Martin Lipp, Felix Oden, Uta Höpken, Gerd Müller, Oliver Daumke, Stephen Marino, Daniel Olal
-
Patent number: 10731163Abstract: An antisense oligonucleotide comprising a sequence targeted to the 3? untranslated region (3? UTR) of the TNFAIP3 (A20) transcript and its use as a medicament, for example in the treatment of cancer or an autoimmune disease.Type: GrantFiled: September 2, 2015Date of Patent: August 4, 2020Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-GemeinschaftInventors: Markus Landthaler, Yasuhiro Murakawa
-
Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
Patent number: 10683309Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: GrantFiled: July 27, 2017Date of Patent: June 16, 2020Assignees: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Michael Bader, Edgar Specker, Susann Matthes, Anja Schütz, Keven Mallow, Maik Grohmann, Marc Nazaré -
Patent number: 10526639Abstract: The present invention relates to the field of analysis of the three-dimensional structure of the genome, i.e., for genome architecture mapping (GAM). The invention provides a method of determining spatial proximity of a plurality of nucleic acid loci in a compartment such as the cell nucleus, by exploiting their co-segregation amongst fractions of that compartment, identified upon separation of the nucleic acid loci from each other depending on their localization in the compartment to obtain a collection of fractions, e.g., by cryo-sectioning or cryo-milling the compartment; determining the presence or absence of the plurality of loci in the fractions; and determining the co-segregation of the plurality of loci. Co-segregation may then be analysed with statistical methods to determine spatial proximity. The method can be used e.g., for determining physical distance between a plurality of loci; and mapping loci and/or genome architecture, e.g.Type: GrantFiled: December 11, 2015Date of Patent: January 7, 2020Assignees: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT, CAMBRIDGE ENTERPRISE LTD.Inventors: Ana Pombo, Paul Edwards, Mario Nicodemi, Antonio Scialdone, Robert Beagrie
-
Patent number: 10377808Abstract: The present invention pertains to novel high avidity antigen recognizing constructs, such as antibodies or T cell receptors, which specifically bind to the melanoma associated antigen (MAGE) A1. The constructs of the invention are particularly useful for the diagnosis, prevention or therapy of tumorous diseases which are characterized by the specific expression of the MAGE-A1 antigen. Furthermore provided are nucleic acids, vectors and host cells—such as CD4 or CD8 positive T cells—which encode, comprise or present the antigen recognizing constructs of the invention. The invention thus provides new means for immune therapy, specifically adoptive T cell therapy, for treating cancer.Type: GrantFiled: January 29, 2014Date of Patent: August 13, 2019Assignee: Max-Delbrück-Centrum Für Molekulare Medizin (MDC) Berlin-BuchInventors: Thomas Blankenstein, Matthias Obenaus, Catarina Leitão
-
XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME
Publication number: 20190161503Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: ApplicationFiled: July 27, 2017Publication date: May 30, 2019Applicants: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Michael BADER, Edgar SPECKER, Susann MATTHES, Anja SCHÜTZ, Keven MALLOW, Maik GROHMANN, Marc NAZARÉ -
Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
Patent number: 10214530Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: GrantFiled: February 24, 2016Date of Patent: February 26, 2019Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZINInventors: Michael Bader, Edgar Specker, Susann Matthes, Anja Schütz, Keven Mallow, Maik Grohmann, Marc Nazaré -
Patent number: 10144782Abstract: The invention relates to humanized antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.Type: GrantFiled: April 30, 2015Date of Patent: December 4, 2018Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFTInventors: Felix Oden, Stephen Marino, Oliver Daumke
-
Patent number: 10118957Abstract: The invention pertains to a means for downregulating or inhibiting or mislocalizing CAR in a cardiac cell for treating/curing a patient who has suffered or is predisposed to suffering a myocardial infarction (MI) or preventing myocardial infarction or complications thereof.Type: GrantFiled: August 5, 2013Date of Patent: November 6, 2018Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCHInventors: Michael Gotthardt, Fabian Freiberg
-
Publication number: 20180135032Abstract: The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or RSDs). Furthermore, applications of these transposase variants, the transposon, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.Type: ApplicationFiled: November 3, 2017Publication date: May 17, 2018Applicant: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZINInventors: Zsuzsanna Izsvak, Zoltan Ivics, Lajos Mates, Namitha Manoj, Carmen-Anisia Judis, Andrea Katzer
-
XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME
Publication number: 20180051025Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: ApplicationFiled: February 24, 2016Publication date: February 22, 2018Applicants: Max-Delbrück-Centrum für Molekulare Medizin, Forschungsverbund Berlin e.V.Inventors: Michael BADER, Edgar SPECKER, Susann MATTHES, Anja SCHÜTZ, Keven MALLOW, Maik GROHMANN, Marc NAZARÉ -
Patent number: 9840696Abstract: The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or RSDs). Furthermore, applications of these transposase variants, the transposon, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.Type: GrantFiled: December 3, 2015Date of Patent: December 12, 2017Assignee: Max-Delbruck-Centrum Fur Molekulare MedizinInventors: Zsuzsanna Izsvak, Zoltan Ivics, Lajos Mates, Namitha Manoj, Carmen-Anisia Judis, Andrea Katzer
-
Publication number: 20170275590Abstract: The invention relates to method for cultivating stem cells in vitro, comprising the following steps: providing a sample comprising stem cells and cultivating the stem cells by subjecting the sample to a treatment for a first period of time. The treatment is carried out under hypothermic conditions having a defined temperature and a defined atmosphere, wherein the temperature does not exceed 15° C. and the atmosphere has an oxygen content not exceeding 21% (v/v). Thereby, the first period of time is 4 days to 4 weeks.Type: ApplicationFiled: August 25, 2015Publication date: September 28, 2017Applicants: CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN, MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCHInventors: Andreas MARG, Simone SPULER
-
Publication number: 20170166649Abstract: The invention relates to humanized antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.Type: ApplicationFiled: April 30, 2015Publication date: June 15, 2017Applicant: MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFTInventors: Felix Oden, Stephen Marino, Oliver Daumke
-
Patent number: 9574017Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.Type: GrantFiled: April 26, 2013Date of Patent: February 21, 2017Assignees: MDC Max-Delbruck-Centrum Fur Molekulare Medizin Berlin-Buch, Fresenius Medical Care Deutschland GmbHInventors: Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube